Early Cancer Detection & Monitoring

Beyond primary site prediction, to diagnostics and monitoring

Oncocross is expanding the potential of early cancer detection, post-treatment monitoring, and clinical application based on blood-based biomarkers and multi-omics data analytics capabilities.

By precisely interpreting cancer-related molecular changes, we are advancing a data-driven diagnostics business that can support patient diagnosis and monitoring.

VALUE PROPOSITION

Application Value

  • Value Proposition 01

    Multi-layered molecular analysis

    Provides a structure for multi-layered analysis of molecular changes in cancer

  • Value Proposition 02

    Early detection potential

    Supports sophisticated interpretation of signals that are difficult to capture with conventional imaging-based approaches

  • Value Proposition 03

    Post-treatment monitoring

    Diverse clinical applications, including tracking post-treatment changes and monitoring signs of recurrence

BUSINESS SIGNIFICANCE

Business Significance

  • Point 01

    Diagnostics Business Expansion Based on Core Technology Assets

    Expanding early cancer detection and monitoring opportunities by leveraging ONCOfind AI®-based analytics capabilities

  • Point 02

    Expansion into Diagnostics and Monitoring Markets

    A business structure that can expand into early cancer detection and post-treatment monitoring

  • Point 03

    Delivering Patient-Centered Clinical Value

    Connecting data-driven analytics insights to real-world diagnostic and clinical decision support

COLLABORATION DIRECTION

Collaboration Direction

  • Collaboration in biomarker discovery and interpretation using clinical and multi-omics data

  • Molecular signal analysis for early cancer detection and post-treatment monitoring

  • Joint research and partnerships to validate diagnostic and clinical applicability

  • Flexible discussion on data analysis, application scope, and collaboration models based on partner needs

Together with Oncocross, we create new opportunities in drug discovery, diagnostics,
and data-driven expansion.

Let's Build the Next Possibility in Precision Medicine

Contact Us